Skip to main content
SpringerLink
Log in

Benign Prostatic Pathology

  • Chapter
  • First Online:
MRI of the Female and Male Pelvis

  • 1958 Accesses

Abstract

The prostate gland is the male organ most commonly afflicted by benign or malignant neoplasms.

Benign prostatic hyperplasia (BPH) represents the most common benign tumor in men after the fifth decade, and its incidence is age related. BPH uniformly originates in the transition zone and determines obstructive and irritative symptoms caused by an increase in size and consistency of the prostate.

Prostatitis can mimic the irritative symptoms of BPH and can be readily identified by urinalysis and culture; moreover, a urinary tract infection can also be a complication of BPH.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. McNeal JE et al (1988) Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12(12):897–906

    Article  CAS  PubMed  Google Scholar 

  2. Nelson WG et al (2004) The role of inflammation in the pathogenesis of prostate cancer. J Urol 172(5 Pt 2):S6–S11; discussion S11–S12

    Article  CAS  PubMed  Google Scholar 

  3. Gandaglia G et al (2013) The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 112(4):432–441

    Article  PubMed  Google Scholar 

  4. Hughes C et al (2005) Molecular pathology of prostate cancer. J Clin Pathol 58(7):673–684

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Jemal A et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55(1):10–30

    Article  PubMed  Google Scholar 

  6. Barqawi AB et al (2005) Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology 65(4):708–712

    Article  PubMed  Google Scholar 

  7. Grossfeld GD, Coakley FV (2000) Benign prostatic hyperplasia: clinical overview and value of diagnostic imaging. Radiol Clin North Am 38(1):31–47

    Article  CAS  PubMed  Google Scholar 

  8. Roddam AW et al (2005) Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 48(3):386–399; discussion 398–399

    Article  CAS  PubMed  Google Scholar 

  9. Berger AP et al (2005) Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate 64(3):240–245

    Article  PubMed  Google Scholar 

  10. Shoskes DA et al (2003) Long-term results of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome. J Urol 169(4):1406–1410

    Article  CAS  PubMed  Google Scholar 

  11. Geramoutsos I et al (2004) Clinical correlation of prostatic lithiasis with chronic pelvic pain syndromes in young adults. Eur Urol 45(3):333–337; discussion 337–338

    Article  PubMed  Google Scholar 

  12. Murphy G et al (2013) The expanding role of MRI in prostate cancer. AJR Am J Roentgenol 201(6):1229–1238

    Article  PubMed  Google Scholar 

  13. Oto A et al (2010) Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 257(3):715–723

    Article  PubMed  Google Scholar 

  14. Barentsz JO et al (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22(4):746–757

    Article  PubMed Central  PubMed  Google Scholar 

  15. Huisman C et al (2001) Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy. Br J Cancer 85(10):1456–1461

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Saremi F et al (2009) Characterization of genitourinary lesions with diffusion-weighted imaging. Radiographics 29(5):1295–1317

    Article  PubMed  Google Scholar 

  17. Nagel KN et al (2013) Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T. Radiology 267(1):164–172

    Article  PubMed  Google Scholar 

  18. McConnell JD (1994) Benign prostatic hyperplasia. J Urol 152(2 Pt 1):459–460

    CAS  PubMed  Google Scholar 

  19. McConnell JD et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387–2398

    Article  CAS  PubMed  Google Scholar 

  20. Hoffman RM, MacDonald R, Wilt TJ (2004) Laser prostatectomy for benign prostatic obstruction. Cochrane Database Syst Rev (1):CD001987

    Google Scholar 

  21. Hoffman RM et al (2004) Transurethral microwave thermotherapy vs transurethral resection for treating benign prostatic hyperplasia: a systematic review. BJU Int 94(7):1031–1036

    Article  PubMed  Google Scholar 

  22. Duclos A et al (2008) Genitourinary pain and inflammation: diagnosis and management. vol 2, pp 175–199

    Google Scholar 

  23. Krieger JN, Riley DE (2002) Prostatitis: what is the role of infection. Int J Antimicrob Agents 19(6):475–479

    Article  CAS  PubMed  Google Scholar 

  24. Mehik A et al (2000) Epidemiology of prostatitis in Finnish men: a population-based cross-sectional study. BJU Int 86(4):443–448

    Article  CAS  PubMed  Google Scholar 

  25. Krieger JN, Ross SO, Riley DE (2002) Chronic prostatitis: epidemiology and role of infection. Urology 60(6 Suppl):8–12; discussion 13

    Article  PubMed  Google Scholar 

  26. Piovesan AC et al (2009) Incidence of histological prostatitis and its correlation with PSA density. Clinics (Sao Paulo) 64(11):1049–1051

    Article  Google Scholar 

  27. Edlin RS et al (2012) Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention. S Afr J Surg 50(4):127–130

    PubMed  Google Scholar 

  28. Jiménez-Cruz JF, Broseta-Rico E (2005) Clasificaciòn, etiologìa, diagnostico y tratamiento de las prostatitis. Otros tipos de prostatitis. Enferm Infecc Microbiol Clin 23(4):47–56

    Article  PubMed  Google Scholar 

  29. Warrick J, Humphrey PA (2012) Nonspecific granulomatous prostatitis. J Urol 187(6):2209–2210

    Article  PubMed  Google Scholar 

  30. Lee HY et al (2012) Xanthogranulomatous prostatitis: a rare entity resembling prostate adenocarcinoma with magnetic resonance image picture. Clin Imaging 36(6):858–860

    Article  PubMed  Google Scholar 

  31. Shoskes DA et al (2007) Incidence and significance of prostatic stones in men with chronic prostatitis/chronic pelvic pain syndrome. Urology 70(2):235–238

    Article  PubMed  Google Scholar 

  32. Collins MM et al (1999) Distinguishing chronic prostatitis and benign prostatic hyperplasia symptoms: results of a national survey of physician visits. Urology 53(5):921–925

    Article  CAS  PubMed  Google Scholar 

  33. Franiel T et al (2008) Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Invest Radiol 43(7):481–487

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Radiology, University of Verona, Policlinico G.B. Rossi, Piazzale Ludovico Antonio Scuro 10, Verona, 37134, Italy

    Teresa Milazzo, Federica Castelli, Beatrice Pedrinolla, Emanuele Demozzi, Riccardo Manfredi & Roberto Pozzi Mucelli

Authors
  1. Teresa Milazzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Federica Castelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Beatrice Pedrinolla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emanuele Demozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Riccardo Manfredi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Roberto Pozzi Mucelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Teresa Milazzo .

Editor information

Editors and Affiliations

  1. Department of Radiology, University of Verona, “G.B.Ross” University Hospital, Verona, Italy

    Riccardo Manfredi

  2. Department of Radiology, University of Verona, “G.B.Ross” University Hospital, Verona, Italy

    Roberto Pozzi Mucelli

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Milazzo, T., Castelli, F., Pedrinolla, B., Demozzi, E., Manfredi, R., Mucelli, R.P. (2015). Benign Prostatic Pathology. In: Manfredi, R., Pozzi Mucelli, R. (eds) MRI of the Female and Male Pelvis. Springer, Cham. https://doi.org/10.1007/978-3-319-09659-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-09659-9_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-09658-2

  • Online ISBN: 978-3-319-09659-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation